维康药业发预亏，预计2025年度归母净亏损1.7亿元至2.45亿元

Group 1 - The core point of the article is that Weikang Pharmaceutical (300878.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of the listed company between 170 million yuan and 245 million yuan [1] - The company anticipates a net loss of 170 million yuan to 245 million yuan after excluding non-recurring gains and losses [1]